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EDITORIAL COMMENTARYFailure to initiate statin therapy during and after percutaneous
coronary interventions negatively affects coronary artery bypass
graft outcomesHarold L. Lazar, MDSee related article on pages 1876-83.Studies have shown that patients who have had a previous
percutaneous coronary intervention (PCI) and subsequently
require coronary artery bypass graft (CABG) surgery
have increased perioperative morbidity and mortality and
decreased long-term survival.1-4 Tran and colleagues3
found that patients with diabetes mellitus who had
previously undergone a PCI and subsequently underwent
CABG surgery had nearly a 3-fold increase in operative
mortality, increased risk of developing a major adverse
cardiac event (MACE), and significantly reduced 2-year
survival compared with patients without a previous PCI.
In an editorial accompanying this study, it was noted that
the use of statin therapy in both groups was especially
low (<40%).5 The question was raised on whether the
outcomes would have improved in the PCI cohort
undergoing CABG if these patients had received statin
therapy after their PCI and before their surgery. This issue
is now addressed in the study by Mannacio and colleagues
in this issue of The Journal of Thoracic and Cardiovascular
Surgery.6 In this study of 2501 patients who had undergone
a previous PCI and now required CABG surgery, 1528
patients were on continuous statin therapy and 973 patients
did not receive a statin until immediately before their
surgery. A propensity-matched conditional logistic
regression analysis showed that continued statin therapy
significantly reduced the risk for in-hospital and 2-year
mortality and MACE. Statins were particularly effective
in those patients who had prolonged crossclamp times and
patients with previous multivessel PCI. Patients on
continuous statin therapy had significantly lower low-
density lipoprotein cholesterol (LDL-c) levels at the time
of surgery (120 28 mg/dL vs 159 39 mg/dL; P<.001).
There were several limitations in this study. It was
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dosages varied widely. Adherence was assessed by the rates
of prescription refills and not by actual documentation that
patients took their medication. Nearly 35% of the patients
had diabetes mellitus but no mention was made of the use
of perioperative glycemic control or the preoperative
glycated hemoglobin values between the groups. The use
of other cardioprotective agents was poor; only 22% of
patients received an angiotensin-converting enzyme
(ACE) inhibitor and only 70% were on a b-blocker at the
time of surgery. Cardiac catheterization data were not
available at the time of the PCI so that the completeness
of the revascularization performed during PCI for both
groups was unknown.
Nevertheless, this study is important in that it adds to
previous reports showing that statins given before CABG
and continued in the postoperative period resulted in
significant decreases in 30-day mortality and MACE and
increased long-term survival.7-10 Furthermore, these
results are particularly important and impressive because
all the patients in both groups received a statin 24 hours
after surgery, which was then continued during the
follow-up period. The fact that statins were particularly
effective in those patients with prolonged crossclamp times
and previous multivessel PCI suggests that these beneficial
effects may have resulted from the decrease in the
inflammatory response both acutely and in those patients
with higher atherosclerotic burdens stemming from the
pleiotropic effects of statins.11,12 These findings support
the current guideline recommendations that all patients
undergoing CABG should receive statin therapy to
achieve a result that will reduce LDL-c levels to less than
100 mg/dL and less than 70 mg/dL in high-risk patients;
and to achieve at least a 30% lowering of LDL-c levels in
all patients.13 It also sends the important message to our
medical colleagues that initiating and sustaining statin
therapy after a PCI will significantly affect the results after
future CABG surgery.
Evidence is now emerging that statins are also beneficial
to patients undergoing PCI. In a meta-analysis of 4805
patients undergoing PCI, statin therapy at the time of
the procedure significantly reduced the incidence of
periprocedural myocardial infarction (MI).14 In a review
of 13 randomized studies involving 3341 patients undergo-
ing PCI, the use of high-dose statin therapy reduced the risk
of an MI or MACE by 44%.15 In a small study involvinggery c November 2014
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tin significantly decreased the incidence of periprocedural
MI and resulted in an 88% reduction in MACE.16 Chan
and colleagues17 showed that statin therapy initiated at
the time of PCI significantly reduced mortality at 30 days
and at 6 months and that the mechanism was independent
of any lowering of lipid levels.17 Several prospective
randomized trials have also demonstrated that statin
pretreatment with fixed doses of a specific statin provides
significant cardioprotection during PCI.16,18,19
The favorable effects of statins may be related to their
ability to decrease inflammatory processes, which are
known to be increased during PCI.11 They have been shown
to reduce C-reactive protein, improve endothelial function,
and reduce platelet activation, which are all involved in the
inflammatory response during PCI.12,20,21
In view of these advantages of statin therapy during and
after PCI, why is the use of statin therapy in these patients
not more common? Several explanations have been
proposed:
1. Economic limitations: these drugs are expensive and
may not be affordable or covered by all existing medical
plans.
2. Physician philosophy: some primary care physicians are
unlikely to begin statin therapy on patients with increase
LDL-c levels if they are asymptomatic.
3. Patient issues: after a revascularization procedure, either
a PCI or CABG, patients feel so much better and their
angina is gone so that they no longer believe it is
necessary to take extra medications and that their disease
is cured.
What can a surgeon do to make sure that patients remain
on statin therapy after their CABG? This becomes
important because in most practices, after surgery and at
the initial postoperative visit, these patients are followed
by cardiologists and primary care physicians whose role
is to make sure that the guidelines for statin therapy after
CABG are followed. This is especially crucial for those pa-
tients who undergo a PCI as their initial revascularization
procedure and may not see a surgeon unless they require
a CABG. In the past, surgeons have been reluctant to
initiate statin therapy during the preoperative or post-
operative period, believing that it was the responsibility
of the cardiologist or referring physician to initiate
lipid-lowering therapy. However, it is now well known
that initiating statin therapy at the time of CABG or an acute
coronary event not only decreases morbidity and mortality
but it is more likely that patients will be more compliant
with taking these medications in the long term. Muhlestein
and colleagues22 found that patients who received a
prescription for a statin on discharge from the hospital
after an acute coronary event had better long-term
compliance and reduced long-term mortality. In the CardiacThe Journal of Thoracic and CarHospitalization Arterial Sclerosis Management Program
(CHAMP), the initiation of statins, ACE inhibitors, aspirin,
and b-blockers after an acute MI before hospital discharge
increased the use of statins from 6% to 86% (P<.01).23 At
the 1-year follow-up, compliance was 91% and 58% of
CHAMP patients had an LDL-c level less than 100 mg/dL
compared with only 6% of pre-CHAMP patients.24 This
resulted in a significant reduction in the incidence of deaths,
MIs, and repeat hospitalization over an 8-year period.
Starting patients on statin therapy in the hospital after
CABG surgery conveys the message to the patient that
this is an important medication that may prevent another
operation and prolong survival. I tell all my patients that
they will need to be on a statin with a targeted level of
less than 100 mg/dL, or less than 70 mg/dL if they have
diabetes, for the rest of their lives. These data are sent to
the referring cardiologist and primary care physician and
are included in the discharge summary. We now know
that revascularization alone is not sufficient to prevent
recurrent ischemic events. By initiating statin therapy in
all our patients undergoing CABG and educating them on
the importance of targeted lipid therapy, we can provide
them with the most optimal surgical as well as medical
therapy to protect them from recurrent ischemic events.
CONCLUSIONS
Patients who have had a previous PCI and subsequently
require CABG surgery have increased perioperative
morbidity and mortality and decreased long-term survival.
However, a study by Mannacio and colleagues6 has shown
that patients who have received continuous statin therapy
since their PCI have reduced risk for in-hospital and
2-year mortality compared with patients who did not
receive statin therapy.
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